PGDx elio tissue complete CDx
Personal Genome Diagnostics, Inc. · Decision date Jul 30, 2026
What did the FDA approve?
FDA records P250036 as an original PMA application. The recorded decision is approval, dated Jul 30, 2026.
FDA approval order statement
PGDx elio tissue complete CDx is a qualitative next-generation sequencing-based in vitro diagnostic device that uses a high-throughput hybridization-based capture technology utilizing DNA isolated from formalin-fixed paraffin embedded tumor tissue. The PGDx elio tissue complete CDx targeted panel can detect single nucleotide variants, small insertions and deletions, copy number amplifications, and translocations. It is intended to be used as a companion diagnostic to identify melanoma patients who may benefit from treatment with the targeted therapies listed in Table 1.1 below in accordance with the approved therapeutic product labeling.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Medical Genetics
- Decision date
- Jul 30, 2026
Regulatory record facts
- Identifier
- P250036
- Regulatory pathway
- Premarket approval application
- Applicant
- Personal Genome Diagnostics, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Jul 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Personal Genome Diagnostics, Inc.
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250036 received
Application receipt date recorded by FDA.
P250036 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250036. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Personal Genome Diagnostics, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3600 Boston St., Suite 10, Blatimore, MD, 21224
Sources and methodology
- Original FDA record: P250036
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


